Home » Topics » Regulatory » EMA

EMA
RSS

ImmunoCellular Therapeutics receives orphan drug status in Europe for ICT-107 in glioblastoma

Feb. 26, 2014

EMA concludes review of Protelos/Osseor

Feb. 24, 2014

GSK's umeclidinium recommended for E.U. approval in treatment of COPD

Feb. 21, 2014

EMA committee recommends approval of BioMarin's Vimizim for Morquio A syndrome

Feb. 21, 2014

Anoro receives positive CHMP opinion for the treatment of COPD

Feb. 21, 2014

European COMP recommends orphan drug designation for ISIS-TTRRx

Feb. 17, 2014

EMA's Committee for Orphan Medicinal Products issues positive opinion on Arikace

Feb. 11, 2014

XBiotech and EMA agree on phase III registration study for Xilonix

Feb. 3, 2014

OPS-202 receives EMA orphan drug designation for management of neuroendocrine tumors

Jan. 30, 2014

EMA committee recommends approval of Bayer's riociguat for two forms of pulmonary hypertension

Jan. 27, 2014

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Innervation can slow, as well as speed, tumor growth, study finds
BioWorld
Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.